The majority of studies reveal that systemic and/or local production of IL-33 exerts a potent inhibitory effect on tumor growth and metastasis by enhancing both adaptive (i.e., effector Th1 and CD8+ T cells) and innate (i.e., NK cells, DCs, and eosinophils) immune components, and yields further synergy in combination with ICB. This evidence concerns the gene IL33 and neoplasm.